Hidradenitis Suppurativa (HS) Market to Reach USD 1315.3 Million by 2035

According to analysts at Vantage Market Research, the Global Hidradenitis Suppurativa (HS) Market size is worth USD 894.3 Million in 2024 and is projected to reach USD 1315.3 Million by 2035, growing at a CAGR (Compound Annual Growth Rate) of 4.9% from 2024 to 2035. Key trends of market include rising adoption of biologics, increased R&D investments, growing patient awareness, expanding treatment access, advancements in diagnostic tools, and emphasis on personalized therapies.

Market Overview

The rise in the prevalence of skin diseases, including conditions like hidradenitis suppurativa (HS), is significantly driving the Hidradenitis Suppurativa (HS) market. Hidradenitis suppurativa is a chronic, inflammatory skin disorder characterized by painful abscesses, tunnels under the skin, and scarring, primarily affecting areas with sweat glands such as the armpits, groin, and under the breasts. The increasing incidence of hidradenitis suppurativa is linked to factors such as genetic predisposition, obesity, smoking, and hormonal changes. Globally, growing prevalence is contributing to heightened demand for effective treatments and driving Hidradenitis Suppurativa (HS) market.

As governments and private sectors around the world continue to prioritize healthcare development, there is a growing emphasis on expanding access to specialized care, improving diagnostic capabilities, and enhancing treatment options for chronic conditions like hidradenitis suppurativa. Rising initiatives by public and private organizations to spread awareness and increasing number of cases of obesity will expand the hidradenitis suppurativa (HS) market. Additionally, high disposable income and changing lifestyle of people will result in the expansion of market. Moreover, rising geriatric population and rising incidences of smoking will enhance the growth rate of the market. 

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

• In May 2022, MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that the first patient has been randomized and dosed, in a U.S. site, in its global Phase 2 clinical trial evaluating sonelokimab, an investigational Nanobody® designed to treat inflammatory disease, in patients with moderate-to-severe hidradenitis suppurativa (HS)

Key Takeaways from the Report

• North America dominated the market with largest market share of 46.50% in 2024. Market is driven by a high prevalence of the condition, increased awareness, and advancements in treatment options
• In 2024, based on the Treatment type, the Medication category accounted for significant market share of 62.30%. Market is driven by several key factors such as rising global prevalence of HS, and alongside increasing awareness and earlier diagnoses
• In 2024, based on the Route of administration, the topical category accounted for significant market share of 69.90%. Market is driven by the growing preference for localized treatments that offer targeted relief with minimal systemic side effects
• In 2024, based on the End Users, the Hospital pharmacies category accounted for significant market share of 66.70%.  An increasing number of initiatives from governmental bodies in enhancing the infrastructure of hospitals pharmacies

Top Companies

• InfraRx N.V.
• Novartis AG
• UCB Biopharma SPRL
• AbbVie Inc
• Eli Lily and Company
• Aristea Therapeutics
• Incyte Corporation
• Janssen Pharmaceuticals
• Priovant Therapeutics
• Amgen Inc
• Aclaris Therapeutics Inc
• Boehringer Ingelheim

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

• In June 2022,  Roivant Sciences and Pfizer announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. Priovant was established in September 2021 through a transaction between Roivant and Pfizer, in which Pfizer licensed oral and topical brepocitinib’s global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25% equity ownership interest in Priovant